Pricing Log in Create free account
Saturday 17 October 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Alkermes plc (ALKS) Business Profile

Updated before January 2025

Company Overview

Alkermes plc (NASDAQ: ALKS) is a fully integrated, global biopharmaceutical company that specializes in developing innovative medicines for the treatment of central nervous system (CNS) disorders and oncology. Founded in 1987, Alkermes has its headquarters in Dublin, Ireland, with a significant operational presence in Waltham, Massachusetts, USA. The company was established with a vision to leverage cutting-edge science to address unmet medical needs, particularly in the areas of mental health, addiction, and cancer.

Alkermes is led by a team of experienced executives, with Richard Pops serving as the Chairman and Chief Executive Officer. Pops has been with the company since 1991 and has played a pivotal role in shaping its strategic direction and growth. The leadership team also includes Iain Brown as Chief Financial Officer and Craig Hopkinson as Chief Medical Officer, among others. Together, they drive the company’s mission to improve patient outcomes through innovative therapies.

Core Business Segments

Alkermes operates across two primary business segments: proprietary products and partnered products. These segments encompass a range of therapies and solutions aimed at addressing critical medical needs.

Proprietary Products

  1. Aristada® (aripiprazole lauroxil): A long-acting injectable antipsychotic used for the treatment of schizophrenia. Aristada offers flexible dosing options and is designed to improve medication adherence among patients.
  2. Vivitrol® (naltrexone for extended-release injectable suspension): A medication approved for the treatment of alcohol dependence and the prevention of relapse to opioid dependence. Vivitrol is a cornerstone of Alkermes’ portfolio, addressing the growing opioid epidemic.
  3. Lybalvi® (olanzapine and samidorphan): A novel antipsychotic medication for the treatment of schizophrenia and bipolar I disorder. Lybalvi is designed to mitigate weight gain associated with olanzapine, a common side effect.

Partnered Products

Alkermes collaborates with leading pharmaceutical companies to develop and commercialize therapies. Key partnered products include:

  1. Risperdal Consta® (risperidone): A long-acting injectable antipsychotic developed in partnership with Janssen Pharmaceuticals.
  2. Invega Sustenna®/Xeplion® (paliperidone palmitate): Another long-acting injectable antipsychotic, also developed with Janssen.
  3. Ampyra® (dalfampridine): A medication for improving walking in patients with multiple sclerosis, developed in collaboration with Acorda Therapeutics.

Business Model

Alkermes employs a hybrid business model that combines proprietary product development with strategic partnerships. This approach allows the company to diversify its revenue streams and leverage external expertise for drug development and commercialization.

Revenue Generation

  1. Proprietary Products: Alkermes generates revenue through the sale of its proprietary medications, such as Vivitrol, Aristada, and Lybalvi.
  2. Royalties and Licensing Fees: The company earns royalties from partnered products like Risperdal Consta and Invega Sustenna. Licensing agreements also contribute to its revenue.
  3. Contract Manufacturing: Alkermes provides contract manufacturing services to its partners, further diversifying its income sources.

Strategic Direction

Alkermes is focused on expanding its portfolio of innovative therapies while maintaining a commitment to sustainability and corporate responsibility. Key strategic priorities include:

  1. Pipeline Expansion: The company is investing in research and development to advance its pipeline of CNS and oncology therapies. Promising candidates include nemvaleukin alfa, an immuno-oncology drug.
  2. Geographic Expansion: Alkermes aims to increase its global footprint by entering new markets and strengthening its presence in existing ones.
  3. Sustainability Goals: The company is committed to reducing its environmental impact and promoting sustainable practices across its operations.
  4. Patient-Centric Approach: Alkermes continues to prioritize patient needs by developing therapies that improve quality of life and address unmet medical needs.

Competitive Landscape

Alkermes operates in a highly competitive biopharmaceutical industry, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  1. Johnson & Johnson: A major player in the CNS space, particularly with its Invega and Risperdal product lines.
  2. Otsuka Pharmaceutical: Known for its Abilify Maintena and Rexulti products, which compete with Alkermes’ antipsychotic offerings.
  3. Teva Pharmaceuticals: A competitor in the generic and specialty drug markets.
  4. Biogen: Focused on neurological disorders, Biogen competes with Alkermes in the CNS segment.
  5. Amgen: A competitor in the oncology space, particularly with its immuno-oncology therapies.

Risk Factors

Alkermes faces several risks that could impact its business operations and financial performance:

  1. Market Dependence: The company relies heavily on the success of its proprietary products, particularly Vivitrol and Aristada. Any decline in sales could significantly affect revenue.
  2. Regulatory Challenges: The biopharmaceutical industry is highly regulated, and any delays or failures in obtaining regulatory approvals could hinder product launches.
  3. Supply Chain Disruptions: Alkermes depends on a complex supply chain for manufacturing and distribution. Disruptions could impact product availability.
  4. Competition: Intense competition from established players and new entrants poses a constant threat.
  5. Litigation Risks: As with many pharmaceutical companies, Alkermes is exposed to potential legal challenges, including patent disputes and product liability claims.

Recent Developments

  1. Lybalvi Launch: Alkermes recently launched Lybalvi, which has been well-received by the medical community for its innovative approach to treating schizophrenia and bipolar I disorder.
  2. Nemvaleukin Alfa: The company is advancing clinical trials for nemvaleukin alfa, a promising candidate in its oncology pipeline.
  3. Sustainability Initiatives: Alkermes has outlined new sustainability goals, including reducing greenhouse gas emissions and improving energy efficiency across its facilities.
  4. COVID-19 Impact: The pandemic has influenced Alkermes’ operations, particularly in terms of supply chain management and clinical trial timelines. However, the company has demonstrated resilience and adaptability.

Investment Considerations

Strengths

  1. Diverse Portfolio: Alkermes offers a balanced mix of proprietary and partnered products, reducing reliance on a single revenue stream.
  2. Strong Pipeline: The company’s focus on CNS and oncology positions it well for future growth.
  3. Experienced Leadership: Alkermes benefits from a seasoned management team with a proven track record.

Risks

  1. Market Dependence: Heavy reliance on a few key products could pose challenges if market dynamics shift.
  2. Regulatory Risks: Delays in approvals or adverse regulatory decisions could impact growth.
  3. Competitive Pressure: Intense competition in the biopharmaceutical space could affect market share.

Conclusion

Alkermes plc is a dynamic biopharmaceutical company with a strong focus on CNS and oncology therapies. Its innovative products, robust pipeline, and strategic partnerships position it as a key player in the industry. While the company faces challenges such as market dependence and regulatory risks, its commitment to innovation and sustainability provides a solid foundation for future growth. Investors seeking exposure to the biopharmaceutical sector may find Alkermes an attractive option, given its diverse portfolio and strategic direction.